168 related articles for article (PubMed ID: 15134516)
1. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
Dogné JM; de Leval X; Hanson J; Frederich M; Lambermont B; Ghuysen A; Casini A; Masereel B; Ruan KH; Pirotte B; Kolh P
Curr Med Chem; 2004 May; 11(10):1223-41. PubMed ID: 15134516
[TBL] [Abstract][Full Text] [Related]
2. From the design to the clinical application of thromboxane modulators.
Dogné JM; Hanson J; de Leval X; Pratico D; Pace-Asciak CR; Drion P; Pirotte B; Ruan KH
Curr Pharm Des; 2006; 12(8):903-23. PubMed ID: 16533159
[TBL] [Abstract][Full Text] [Related]
3. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators.
de Leval X; Hanson J; David JL; Masereel B; Pirotte B; Dogné JM
Curr Med Chem; 2004 May; 11(10):1243-52. PubMed ID: 15134517
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.
Kontogiorgis C; Hadjipavlou-Litina D
Curr Med Chem; 2010; 17(28):3162-214. PubMed ID: 20666724
[TBL] [Abstract][Full Text] [Related]
6. New trends in thromboxane and prostacyclin modulators.
Dogné JM; de Leval X; Delarge J; David JL; Masereel B
Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
8. New developments on thromboxane modulators.
Dogné JM; Hanson J; de Leval X; Masereel B; Kolh P; Pirotte B
Mini Rev Med Chem; 2004 Aug; 4(6):649-57. PubMed ID: 15279599
[TBL] [Abstract][Full Text] [Related]
9. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
10. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.
de Leval X; Dassesse T; Dogné JM; Waltregny D; Bellahcène A; Benoit V; Pirotte B; Castronovo V
J Pharmacol Exp Ther; 2006 Sep; 318(3):1057-67. PubMed ID: 16720756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
Lakin KM; Makarov VA; Novikova NV; Tret'iak VM; Rukazenkov IuE
Farmakol Toksikol; 1984; 47(2):67-79. PubMed ID: 6425078
[No Abstract] [Full Text] [Related]
14. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
15. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
Rolin S; Dogne JM; Vastersaegher C; Hanson J; Masereel B
Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):75-86. PubMed ID: 15560117
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation.
de Leval X; Benoit V; Delarge J; Julémont F; Masereel B; Pirotte B; Merville MP; David JL; Dogné JM
Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):55-9. PubMed ID: 12538091
[TBL] [Abstract][Full Text] [Related]
18. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
Sprague PW; Heikes JE; Harris DN; Greenberg R
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
[No Abstract] [Full Text] [Related]
19. The biochemical pharmacology of thromboxane synthase inhibition in man.
FitzGerald GA; Reilly IA; Pedersen AK
Circulation; 1985 Dec; 72(6):1194-201. PubMed ID: 3905048
[TBL] [Abstract][Full Text] [Related]
20. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.
Bunting S; Moncada S; Vane JR
Br Med Bull; 1983 Jul; 39(3):271-6. PubMed ID: 6354352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
